TGFBR2 (Transforming growth factor, beta receptor II) is a transmembrane serine/threonine kinase that regulates a range of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. It participates in the canonical SMAD-dependent TGF-beta signaling cascade and is also involved in non-canonical, SMAD-independent TGF-beta signaling pathways. Mutations in TGFBR2 are associated with various cancers and diseases such as Osler-Weber-Rendu syndrome, Marfan syndrome, and Loeys-Deitz aortic aneurysm syndrome. In cervical cancer, downregulation of TGFBR2 alongside upregulated TERT is correlated with poor prognosis. In immunohistochemistry of normal tissue, TGFBR2 has membranous positivity in all tissues throughout the body. References: The UniProt Consortium. Nucleic Acids Res. 47: D506-515 (2019); Nucleic Acids Res. 2016 Jan 4;44(D1):D733-45, PMID:26553804; Sci Rep 7, 41670 (2017), DOI: 10.1038/srep41670;